What Is the First-Line Treatment for Fibromuscular Dysplasia?

Fibromuscular dysplasia (FMD) is a non-inflammatory, non-atherosclerotic arterial disease. This page outlines the standard first-line management approach for patients with FMD.

Management of FMD targets prevention of vascular complications. First-line intervention is recommended in the absence of contraindications, with the goal of reducing risk to the patient.

Treatment approach

First-line management centres on antiplatelet therapy to reduce the risk of thrombotic and thromboembolic complications. The complete protocol — including specific agents, criteria for use, and clinical guidance — is available in full below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/1358863X18821816

In the absence of contraindication, antiplatelet therapy (i.e. aspirin 75–100 mg daily) is reasonable for patients with FMD to prevent thrombotic and thromboembolic complications.

View source ↗